phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2022-1-15-30phgenomics-242Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYПервая фаза метаболизма антипсихотиков в печени: роль окисленияFirst phase of antipsychotic metabolism in the liver: the role of oxidationhttps://orcid.org/0000-0002-2840-837XШнайдерН. А.ShnayderN. A.

д. м. н., профессор, в. н. с., заместитель руководителя Института персонализированной психиатрии и неврологии

Санкт-Петербург

в. н. с.

Красноярск

 

Dr. Sci. (Med.), Professor, Leading Researcher, Deputy Head of the Institute of Personalized Psychiatry and Neurology

St.-Petersburg

Leading Researcher of the Center for Collective use «Molecular and Cellular Technologies»

Krasnoyarsk

naschnaider@yandex.ruhttps://orcid.org/0000-0001-5391-0786ХасановаА. К.KhasanovaA. K.

лаборант кафедры психиатрии

Москва

Laboratory assistant of the Department of Psychiatry

Moscow

abdyrahmanova_peri@mail.ruhttps://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

д. м. н., гл. н. с., руководитель Института персонализированной психиатрии и неврологии

Санкт-Петербург

Dr. Sci. (Med.), General Researcher, Head of the Instituteof Personalized Psychiatry and Neurology

St.-Petersburg

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В. М. Бехтерева» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет имени профессора В. Ф. Войно-Ясенецкого» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution V. M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Russian Federation Ministry of Health; Federal State Budgetary Educational Institution of Higher Education “Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University” of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Postgraduate Education” of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии им. В. М. Бехтерева» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution V. M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Russian Federation Ministry of HealthRussian Federation202227022023011530Copyright © Шнайдер Н.А., Хасанова А.К., Насырова Р.Ф., 20232023Шнайдер Н.А., Хасанова А.К., Насырова Р.Ф.Shnayder N.A., Khasanova A.K., Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/242

В данной статье обсуждаются вопросы, освещающие роль метаболизма антипсихотиков (АП) в печени. Различают три фазы метаболизма АП. Цитохром Р450 монооксигеназа, оксидаза со смешанными функциями, играет ключевую роль в метаболизме большинства АП, участвуя в его первой фазе. Функциональная активность изоферментов цитохрома Р450 зависит от носительства однонуклеотидных вариантов (ОНВ) генов, кодирующих эти изоферменты, а также от межлекарственных взаимодействий. Функциональная активность изоферментов цитохрома Р450 может влиять на эффективность и безопасность применения АП. Практикующему врачу-психиатру важно знать пути окисления АП для предотвращения нежелательных реакций (НР) и нежелательных межлекарственных взаимодействий, что впоследствии повысит эффективность и безопасность терапии АП.

This article discusses issues related to the role of biotransformation or metabolism of antipsychotics (APs) in the liver. There are three phases of APs metabolism. Cytochrome P450 monooxygenase, an oxidase with mixed functions, plays a key role in the biotransformation of most APs, participating in the first phase of metabolism. The functional activity of cytochrome P450 enzymes depends on the carriage of single nucleotide variants (SNVs) of the genes encoding these enzymes, as well as on drug-drug interactions. The functional activity of cytochrome P450 enzymes may affect the efficacy and safety of the use of APs. It is important for a practicing psychiatrist to know the pathways of APs oxidation to prevent adverse drug reactions (ADRs) and unwanted drug-drug interactions, which will subsequently increase the efficacy and safety of AP therapy

окислениеантипсихотикпервая фаза метаболизмацитохром Р450ферментoxidationantipsychoticfirst phase of metabolismcytochrome P450enzymeReferencesFinkel R, Clark MA, Cubeddu LX. Pharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2008. P. 151.Finkel R, Clark MA, Cubeddu LX. Pharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2008. P. 151.Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015 Jun;114(1):169–179. DOI: 10.1093/bmb/ldv017Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015 Jun;114(1):169–179. DOI: 10.1093/bmb/ldv017Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561–1572. DOI: 10.1016/S0140-6736(15)00241-XGrande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561–1572. DOI: 10.1016/S0140-6736(15)00241-XCaroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011 Feb;29(1):127–148, viii. DOI: 10.1016/j.ncl.2010.10.002Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011 Feb;29(1):127–148, viii. DOI: 10.1016/j.ncl.2010.10.002Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2009. Pp. 4113–4119.Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2009. Pp. 4113–4119.Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406. DOI: 10.1146/annurev-med-050911-161504Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406. DOI: 10.1146/annurev-med-050911-161504Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010 Jul;11(6):516– 525. DOI: 10.2174/138920010791636202Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010 Jul;11(6):516– 525. DOI: 10.2174/138920010791636202Rourke JL, Sinal CJ. Biotransformation/Metabolism. Encycl. Toxicol. 2014;1:490–502.Rourke JL, Sinal CJ. Biotransformation/Metabolism. Encycl. Toxicol. 2014;1:490–502.Shanu-Wilson J, Evans L, Wrigley S, Steele J, Atherton J, Boer J. Biotransformation: Impact and Application of Metabolism in Drug Discovery ACS Med Chem Lett. 2020 Aug 28;11(11):2087–2107. DOI: 10.1021/acsmedchemlett.0c00202Shanu-Wilson J, Evans L, Wrigley S, Steele J, Atherton J, Boer J. Biotransformation: Impact and Application of Metabolism in Drug Discovery ACS Med Chem Lett. 2020 Aug 28;11(11):2087–2107. DOI: 10.1021/acsmedchemlett.0c00202Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry. 1999;11(3):145–158. DOI: 10.1023/a:1022312111429Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry. 1999;11(3):145–158. DOI: 10.1023/a:1022312111429Correia MA. Drug biotransformation. In Basic & Clinical Pharmacology, 14th ed.; Katzung BG, Ed. New York, NY, USA: McGraw Hill Education, 2017. Volume 1, pp. 56–74.Correia MA. Drug biotransformation. In Basic & Clinical Pharmacology, 14th ed.; Katzung BG, Ed. New York, NY, USA: McGraw Hill Education, 2017. Volume 1, pp. 56–74.Josephy DP, Guengerich PF, Miners JO. “Phase I and Phase II” drug metabolism: terminology that we should phase out? Drug Metab Rev. 2005;37(4):575–580. DOI: 10.1080/03602530500251220Josephy DP, Guengerich PF, Miners JO. “Phase I and Phase II” drug metabolism: terminology that we should phase out? Drug Metab Rev. 2005;37(4):575–580. DOI: 10.1080/03602530500251220De Bruyn Kops C, Šícho M, Mazzolari A, Kirchmair J. GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of Xenobiotics. Chem Res Toxicol. 2021;34(2):286–299. DOI: 10.1021/acs.chemrestox.0c00224De Bruyn Kops C, Šícho M, Mazzolari A, Kirchmair J. GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of Xenobiotics. Chem Res Toxicol. 2021;34(2):286–299. DOI: 10.1021/acs.chemrestox.0c00224Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001;14(6):611–650. DOI: 10.1021/tx0002583Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001;14(6):611–650. DOI: 10.1021/tx0002583Bachmann K. Drug Metabolism. Pharmacology. 2009;8:131–173.Bachmann K. Drug Metabolism. Pharmacology. 2009;8:131–173.Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci. 1997;19(6):255–263. DOI: 10.1023/a:1008668913093Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci. 1997;19(6):255–263. DOI: 10.1023/a:1008668913093Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2018;19(1):38–54. DOI: 10.2174/1389450118666170125144557Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2018;19(1):38–54. DOI: 10.2174/1389450118666170125144557Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561– 597. DOI: 10.2174/1389200023337054Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561– 597. DOI: 10.2174/1389200023337054Pandey AV, Flück CE. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol Ther. 2013 May;138(2):229– 254. DOI: 10.1016/j.pharmthera.2013.01.010Pandey AV, Flück CE. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol Ther. 2013 May;138(2):229– 254. DOI: 10.1016/j.pharmthera.2013.01.010Jensen K, Møller BL. Plant NADPH-cytochrome P450 oxidoreductases. Phytochemistry. 2010;71(2–3):132–141. DOI: 10.1016/j.phytochem.2009.10.017Jensen K, Møller BL. Plant NADPH-cytochrome P450 oxidoreductases. Phytochemistry. 2010;71(2–3):132–141. DOI: 10.1016/j.phytochem.2009.10.017Klein MT, Torry LA, Wu BC, Townsend SH, Paspek SC. Hydrolysis in supercritical water: Solvent effects as a probe of the reaction mechanism. J Supercrit Fluids. 1990;3:222–227. DOI: org/10.1016/0896-8446(90)90026-IKlein MT, Torry LA, Wu BC, Townsend SH, Paspek SC. Hydrolysis in supercritical water: Solvent effects as a probe of the reaction mechanism. J Supercrit Fluids. 1990;3:222–227. DOI: org/10.1016/0896-8446(90)90026-INelson DR. Cytochrome P450 diversity in the tree of life. Biochim Biophys Acta Proteins Proteom. 2018 Jan;1866(1):141–154. DOI: 10.1016/j.bbapap.2017.05.003Nelson DR. Cytochrome P450 diversity in the tree of life. Biochim Biophys Acta Proteins Proteom. 2018 Jan;1866(1):141–154. DOI: 10.1016/j.bbapap.2017.05.003Клиническая психофармакогенетика / под ред. Насыровой Р. Ф., Незнанова Н. Г. СПб.: Издательство ДЕАН, 2019. С. 97–174. [Klinicheskaya psikhofarmakogenetika. Ed by. Nasyrova RF, Neznanova NG. SPb.: Izdatel’stvo DEAN, 2019. (In Russ).].Клиническая психофармакогенетика / под ред. Насыровой Р. Ф., Незнанова Н. Г. СПб.: Издательство ДЕАН, 2019. С. 97–174. [Klinicheskaya psikhofarmakogenetika. Ed by. Nasyrova RF, Neznanova NG. SPb.: Izdatel’stvo DEAN, 2019. (In Russ).].Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev. 2011;43(3):346–361. DOI: 10.3109/03602532.2010.549492Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev. 2011;43(3):346–361. DOI: 10.3109/03602532.2010.549492Thomas LP, Laszlo K. Rapid Review Pharmacology. 3rd ed. The Netherlands (Amsterdam): Elsevier, 2010. Pp. 7–9.Thomas LP, Laszlo K. Rapid Review Pharmacology. 3rd ed. The Netherlands (Amsterdam): Elsevier, 2010. Pp. 7–9.Shnayder NA, Abdyrakhmanova AK, Nasyrova RF. Phase I of antipsychotics metabolism and its pharmacogenetic testing. Personalized Psychiatry and Neurology. 2022;2(1):4–21. DOI: 10.52667/2712-9179-2022-2-1-4-21Shnayder NA, Abdyrakhmanova AK, Nasyrova RF. Phase I of antipsychotics metabolism and its pharmacogenetic testing. Personalized Psychiatry and Neurology. 2022;2(1):4–21. DOI: 10.52667/2712-9179-2022-2-1-4-21Nelson DR. The cytochrome p450 homepage. Hum Genomics. 2009;4(1):59–65. DOI: 10.1186/1479-7364-4-1-59Nelson DR. The cytochrome p450 homepage. Hum Genomics. 2009;4(1):59–65. DOI: 10.1186/1479-7364-4-1-59Guengerich FP. Mechanisms of cytochrome P450-catalyzed oxidations. ACS Catal. 2018;8(12):10964–10976. DOI: 10.1021/acscatal.8b03401Guengerich FP. Mechanisms of cytochrome P450-catalyzed oxidations. ACS Catal. 2018;8(12):10964–10976. DOI: 10.1021/acscatal.8b03401Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1–2):413–580. DOI: 10.3109/03602539709037591Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1–2):413–580. DOI: 10.3109/03602539709037591Shnayder NA, Abdyrakhmanova AK, Nasyrova RF. Oxidation of antipsychotics. Encyclopedia. 2022;2:974–989. DOI: 10.3390/encyclopedia2020064Shnayder NA, Abdyrakhmanova AK, Nasyrova RF. Oxidation of antipsychotics. Encyclopedia. 2022;2:974–989. DOI: 10.3390/encyclopedia2020064Le T, Bhushan V, Sochat M, Vaidyanathan V, Schimansky S, Abrams J, Kallianos K. First Aid for the USMLE Step 1. 30th ed. NY: McGraw Hill Education, 2020. Pp. 230, 252.Le T, Bhushan V, Sochat M, Vaidyanathan V, Schimansky S, Abrams J, Kallianos K. First Aid for the USMLE Step 1. 30th ed. NY: McGraw Hill Education, 2020. Pp. 230, 252.Machalz D, Pach S, Bermudez M, Bureik M, Wolber G. Structural insights into understudied human cytochrome P450 enzymes. Drug Discov Today. 2021;26(10):2456–2464. DOI: 10.1016/j.drudis.2021.06.006Machalz D, Pach S, Bermudez M, Bureik M, Wolber G. Structural insights into understudied human cytochrome P450 enzymes. Drug Discov Today. 2021;26(10):2456–2464. DOI: 10.1016/j.drudis.2021.06.006Go.drugbank.com [Internet]: открытая база данных. Drug bank [cited 2022 Oct 19]. URL: https://go.drugbank.com/Go.drugbank.com [Internet]: открытая база данных. Drug bank [cited 2022 Oct 19]. URL: https://go.drugbank.com/Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5(5):569–585. DOI: 10.1586/ecp.12.39Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5(5):569–585. DOI: 10.1586/ecp.12.39Department of Medicine Clinical Pharmacology [Internet]. Drug Interactions Flockhart Table [cited 2022 Oct 19]. URL: https://druginteractions.medicine.iu.edu/MainTable.aspx.Department of Medicine Clinical Pharmacology [Internet]. Drug Interactions Flockhart Table [cited 2022 Oct 19]. URL: https://druginteractions.medicine.iu.edu/MainTable.aspx.Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology—with emphasis on cytochrome р450. Toxicol Sci. 2011;120(1):1–13. DOI: 10.1093/toxsci/kfq374Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology—with emphasis on cytochrome р450. Toxicol Sci. 2011;120(1):1–13. DOI: 10.1093/toxsci/kfq374Medsafe: New Zealand Medicines and Medical Devices Safety Authority [Internet]. Drug Metabolism — The Importance of Cytochrome P450 3A4 [cited 2022 Oct 19]. URL: https://www.medsafe.govt.nz/profs/puarticles/march2014drugmetabolismcytochromep4503a4.htm.Medsafe: New Zealand Medicines and Medical Devices Safety Authority [Internet]. Drug Metabolism — The Importance of Cytochrome P450 3A4 [cited 2022 Oct 19]. URL: https://www.medsafe.govt.nz/profs/puarticles/march2014drugmetabolismcytochromep4503a4.htm.Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96(3):340–348. DOI: 10.1038/clpt.2014.129Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96(3):340–348. DOI: 10.1038/clpt.2014.129Bondy B, Zill P. Psychopharmacogenetics — a challenge for pharmacotherapy in psychiatry. World J Biol Psychiatry. 2001;2(4):178–183. DOI: 10.3109/15622970109026806Bondy B, Zill P. Psychopharmacogenetics — a challenge for pharmacotherapy in psychiatry. World J Biol Psychiatry. 2001;2(4):178–183. DOI: 10.3109/15622970109026806Насырова Р. Ф., Иванов М. В., Незнанов Н. Г. Введение в психофармакогенетику: монография. СПб.: Издательский центр СПб. НИПНИ им. В. М. Бехтерева, 2015. 272 с. [Nasyrova RF, Ivanov MV, Neznanov NG. Vvedenie v psikhofarmakogenetiku: monografiya. SPb.: Izdatel’skii tsentr SPb. NIPNI im. V. M. Bekhtereva, 2015. (In Russ).].Насырова Р. Ф., Иванов М. В., Незнанов Н. Г. Введение в психофармакогенетику: монография. СПб.: Издательский центр СПб. НИПНИ им. В. М. Бехтерева, 2015. 272 с. [Nasyrova RF, Ivanov MV, Neznanov NG. Vvedenie v psikhofarmakogenetiku: monografiya. SPb.: Izdatel’skii tsentr SPb. NIPNI im. V. M. Bekhtereva, 2015. (In Russ).].Абдырахманова А. К., Шнайдер Н. А., Насырова Р. Ф. Клинический случай поздней фармакогенетической диагностики нежелательных реакций на фоне психофармакотерапии у пациентки с рекуррентным депрессивным расстройством. Фармакогенетика и фармакогеномика. 2021;(2):21–23. [Abdyrakhmanova AK, Shnaider NA, Nasyrova RF. Klinicheskii sluchai pozdnei farmakogeneticheskoi diagnostiki nezhelatel’nykh reaktsii na fone psikhofarmakoterapii u patsientki s rekurrentnym depressivnym rasstroistvom. Farmakogenetika i farmakogenomika = Pharmacogenetics and pharmacogenomics. 2021;(2):21–23. (In Russ).]. DOI: 10.37489/2588-0527-2021-2-21-23Абдырахманова А. К., Шнайдер Н. А., Насырова Р. Ф. Клинический случай поздней фармакогенетической диагностики нежелательных реакций на фоне психофармакотерапии у пациентки с рекуррентным депрессивным расстройством. Фармакогенетика и фармакогеномика. 2021;(2):21–23. [Abdyrakhmanova AK, Shnaider NA, Nasyrova RF. Klinicheskii sluchai pozdnei farmakogeneticheskoi diagnostiki nezhelatel’nykh reaktsii na fone psikhofarmakoterapii u patsientki s rekurrentnym depressivnym rasstroistvom. Farmakogenetika i farmakogenomika = Pharmacogenetics and pharmacogenomics. 2021;(2):21–23. (In Russ).]. DOI: 10.37489/2588-0527-2021-2-21-23Abdyrakhmanova AK, Nasyrova RF. Pharmacogenetic testing of cytochrome p450 metabolizing enzymes in 28-year-old man with treatmentresistant schizophrenia. Personalized Psychiatry and Neurology. 2022;2(1):81–88. DOI: 10.52667/2712-9179-2022-2-1-81-88Abdyrakhmanova AK, Nasyrova RF. Pharmacogenetic testing of cytochrome p450 metabolizing enzymes in 28-year-old man with treatmentresistant schizophrenia. Personalized Psychiatry and Neurology. 2022;2(1):81–88. DOI: 10.52667/2712-9179-2022-2-1-81-88Laika B, Leucht S, Heres S, Steimer W. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to costeffectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 2009;9(6):395–403. DOI: 10.1038/tpj.2009.23Laika B, Leucht S, Heres S, Steimer W. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to costeffectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 2009;9(6):395–403. DOI: 10.1038/tpj.2009.23Zhuravlev NM, Shnayder NA, Vaiman EE, Abdyrakhmanova AK, Petrova MM, Bochanova EN, Romanova IV, Gavrilyuk OA, Lareva NV, Nasyrova RF. Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk. Personalized Psychiatry and Neurology. 2022;2(1):22–45. DOI: 10.52667/2712-9179-2022-2-1-23-45Zhuravlev NM, Shnayder NA, Vaiman EE, Abdyrakhmanova AK, Petrova MM, Bochanova EN, Romanova IV, Gavrilyuk OA, Lareva NV, Nasyrova RF. Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk. Personalized Psychiatry and Neurology. 2022;2(1):22–45. DOI: 10.52667/2712-9179-2022-2-1-23-45Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–396.Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–396.Кукес В. Г., Иванец Н. Н., Сычёв Д. А., Псарева Н. А. Фармакогенетика системы цитохрома Р-450 и безопасность терапии антидепрессантами. Биомедицина. 2014;1(1):67–80. [Kukes VG, Ivanets NN, Sychev DA, Psareva NA. Cytochrome P-450 pharmacogenetics and antidepressants treatment safety. Journal Biomed. 2014;1(1):67–80. (In Russ).]. URL: https://journal.scbmt.ru/jour/article/view/305/210. Ссылка активна на 01.12.2022.Кукес В. Г., Иванец Н. Н., Сычёв Д. А., Псарева Н. А. Фармакогенетика системы цитохрома Р-450 и безопасность терапии антидепрессантами. Биомедицина. 2014;1(1):67–80. [Kukes VG, Ivanets NN, Sychev DA, Psareva NA. Cytochrome P-450 pharmacogenetics and antidepressants treatment safety. Journal Biomed. 2014;1(1):67–80. (In Russ).]. URL: https://journal.scbmt.ru/jour/article/view/305/210. Ссылка активна на 01.12.2022.Dobrodeeva VS, Abdyrahmanova AK, Nasyrova RF. Personalized approach to antipsychotic-induced weight gain prognosis. Personalized Psychiatry and Neurology. 2021;1(1):3–10. DOI: 10.52667/2712-9179-2021-1-1-3-10Dobrodeeva VS, Abdyrahmanova AK, Nasyrova RF. Personalized approach to antipsychotic-induced weight gain prognosis. Personalized Psychiatry and Neurology. 2021;1(1):3–10. DOI: 10.52667/2712-9179-2021-1-1-3-10Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 2013;368(1612): 20120431. DOI: 10.1098/rstb.2012.0431Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 2013;368(1612): 20120431. DOI: 10.1098/rstb.2012.0431GeneCards [Internet]: открытая база данных. The Human Gene Database [cited 2022 Oct 19]. URL: https://www.genecards.org/.GeneCards [Internet]: открытая база данных. The Human Gene Database [cited 2022 Oct 19]. URL: https://www.genecards.org/.Proteinatlas.org [Internet]. The Humаn Protein Atlas [cited 2022 Oct 19]. URL: https://www.proteinatlas.org/.Proteinatlas.org [Internet]. The Humаn Protein Atlas [cited 2022 Oct 19]. URL: https://www.proteinatlas.org/.Kawajiri K. CYP1A1. IARC Sci Publ. 1999;(148):159–172.Kawajiri K. CYP1A1. IARC Sci Publ. 1999;(148):159–172.Guo J, Zhu X, Badawy S, et al. Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. Curr Drug Metab. 2021;22(1):40–49. DOI: 10.2174/1389200221999210101233135Guo J, Zhu X, Badawy S, et al. Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. Curr Drug Metab. 2021;22(1):40–49. DOI: 10.2174/1389200221999210101233135Hong CC, Tang BK, Rao V, et al. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res. 2004;6(4):R338–51. DOI: 10.1186/bcr797Hong CC, Tang BK, Rao V, et al. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res. 2004;6(4):R338–51. DOI: 10.1186/bcr797Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact. 2012;27(2):73–88. DOI: 10.1515/dmdi-2012-0001Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact. 2012;27(2):73–88. DOI: 10.1515/dmdi-2012-0001Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of сytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241. DOI: 10.1124/pr.115.011411Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of сytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241. DOI: 10.1124/pr.115.011411Waring RH. Cytochrome P450: genotype to phenotype. Xenobiotica. 2020;50(1):9–18. DOI: 10.1080/00498254.2019.1648911Waring RH. Cytochrome P450: genotype to phenotype. Xenobiotica. 2020;50(1):9–18. DOI: 10.1080/00498254.2019.1648911Amorosi CJ, Chiasson MA, McDonald MG, et al. Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. Am J Hum Genet. 2021;108(9):1735–1751. DOI: 10.1016/j.ajhg.2021.07.001Amorosi CJ, Chiasson MA, McDonald MG, et al. Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. Am J Hum Genet. 2021;108(9):1735–1751. DOI: 10.1016/j.ajhg.2021.07.001Zhu-Ge J, Yu YN. Enzyme activity analysis of CYP2C18 with exon 5 skipped. Acta Pharmacol Sin. 2004;25(8):1065–1059.Zhu-Ge J, Yu YN. Enzyme activity analysis of CYP2C18 with exon 5 skipped. Acta Pharmacol Sin. 2004;25(8):1065–1059.Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–183. DOI: 10.1159/000028398Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–183. DOI: 10.1159/000028398Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13. DOI: 10.1038/sj.tpj.6500285Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13. DOI: 10.1038/sj.tpj.6500285Guengerich FP. Cytochrome P450 2E1 and its roles in disease. Chem Biol Interact. 2020;322:109056. DOI: 10.1016/j.cbi.2020.109056Guengerich FP. Cytochrome P450 2E1 and its roles in disease. Chem Biol Interact. 2020;322:109056. DOI: 10.1016/j.cbi.2020.109056Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96(3):340–348. DOI: 10.1038/clpt.2014.129Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96(3):340–348. DOI: 10.1038/clpt.2014.129Smith SA, Colley HE, Sharma P, et al. Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents. Exp Dermatol. 2018;27(5):473–475. DOI: 10.1111/exd.13483Smith SA, Colley HE, Sharma P, et al. Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents. Exp Dermatol. 2018;27(5):473–475. DOI: 10.1111/exd.13483Li H, Lampe JN. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Arch Biochem Biophys. 2019;673:108078. DOI: 10.1016/ j.abb.2019.108078Li H, Lampe JN. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Arch Biochem Biophys. 2019;673:108078. DOI: 10.1016/ j.abb.2019.108078Brandl EJ, Chowdhury NI, Tiwari AK, et al. Genetic variation in CYP3A43 is associated with response to antipsychotic medication. J Neural Transm (Vienna). 2015;122(1):29–34. DOI: 10.1007/s00702-014-1298-8Brandl EJ, Chowdhury NI, Tiwari AK, et al. Genetic variation in CYP3A43 is associated with response to antipsychotic medication. J Neural Transm (Vienna). 2015;122(1):29–34. DOI: 10.1007/s00702-014-1298-8Javaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol. 1994;34(4):286–295. DOI: 10.1002/j.1552-4604.1994.tb01995.xJavaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol. 1994;34(4):286–295. DOI: 10.1002/j.1552-4604.1994.tb01995.xИващенко Д. В., Насырова Р. Ф., Иванов М. В., Незнанов Н. Г. История фармакогенетики в психиатрии. Фармакогенетика и фармакогеномика. 2015;(2):33–40. [Ivashchenko DV, Nasyrova RF, Ivanov MV, Neznanov NG. The history of pharmacogenetics in psychiatry. Pharmacogenetics and Pharmacogenomics. 2015;(2):33–40. (In Russ).]. URL: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/178?locale=ru_RU. Ссылка активна на 01.12.2022.Иващенко Д. В., Насырова Р. Ф., Иванов М. В., Незнанов Н. Г. История фармакогенетики в психиатрии. Фармакогенетика и фармакогеномика. 2015;(2):33–40. [Ivashchenko DV, Nasyrova RF, Ivanov MV, Neznanov NG. The history of pharmacogenetics in psychiatry. Pharmacogenetics and Pharmacogenomics. 2015;(2):33–40. (In Russ).]. URL: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/178?locale=ru_RU. Ссылка активна на 01.12.2022.Иващенко Д. В., Сосин Д. Н., Кирничная К. А., Ершов Е. Е., Тараскина А. Е., Иванов М. В., Сычёв Д. А., Насырова Р. Ф., Незнанов Н. Г. Экономическая целесообразность фармакогенетического тестирования при назначении антипсихотиков. Фармакогенетика и фармакогеномика. 2015;(1):30–39. [Ivashchenko DV, Sosin DN, Kirnichnaya KA, Ershov EE, Taraskina AE, Ivanov MV, Sychev DA, Nasyrova RF, Neznanov NG. The economic feasibility of pharmacogenetic-based prescribing of antipsychotics: a review. Pharmacogenetics and Pharmacogenomics. 2015;(1):30–39. (In Russ).].Иващенко Д. В., Сосин Д. Н., Кирничная К. А., Ершов Е. Е., Тараскина А. Е., Иванов М. В., Сычёв Д. А., Насырова Р. Ф., Незнанов Н. Г. Экономическая целесообразность фармакогенетического тестирования при назначении антипсихотиков. Фармакогенетика и фармакогеномика. 2015;(1):30–39. [Ivashchenko DV, Sosin DN, Kirnichnaya KA, Ershov EE, Taraskina AE, Ivanov MV, Sychev DA, Nasyrova RF, Neznanov NG. The economic feasibility of pharmacogenetic-based prescribing of antipsychotics: a review. Pharmacogenetics and Pharmacogenomics. 2015;(1):30–39. (In Russ).].Насырова Р. Ф., Добродеева В. С., Скопин С. Д., Шнайдер Н. А., Незнанов Н. Г. Проблемы и перспективы внедрения фармакогенетического тестирования в реальной клинической практике в Российской Федерации. Вестник психиатрии, неврологии и нейрохирургии. 2020;(3):2–7. [Nasyrova RF, Dobrodeeva VS, Skopin SD, Shnaider NA, Neznanov NG. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;(3):2–7. (In Russ).]. DOI: 10.33920/med-01-2003-01Насырова Р. Ф., Добродеева В. С., Скопин С. Д., Шнайдер Н. А., Незнанов Н. Г. Проблемы и перспективы внедрения фармакогенетического тестирования в реальной клинической практике в Российской Федерации. Вестник психиатрии, неврологии и нейрохирургии. 2020;(3):2–7. [Nasyrova RF, Dobrodeeva VS, Skopin SD, Shnaider NA, Neznanov NG. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020;(3):2–7. (In Russ).]. DOI: 10.33920/med-01-2003-01Сычёв Д. А., Кукес В. Г., Ташенова А. И. Фармакогенетическое тестирование — новая медицинская технология. Медицинские технологии. Оценка и выбор. 2010;(2):39–43. [Sychev DA, Kukes VG, Tashenova AI. Pharmacogenetic Testing: a New Medical Technology. Meditsinskie tekhnologii. Otsenka i vybor. 2010;(2):39–43. (In Russ).].Сычёв Д. А., Кукес В. Г., Ташенова А. И. Фармакогенетическое тестирование — новая медицинская технология. Медицинские технологии. Оценка и выбор. 2010;(2):39–43. [Sychev DA, Kukes VG, Tashenova AI. Pharmacogenetic Testing: a New Medical Technology. Meditsinskie tekhnologii. Otsenka i vybor. 2010;(2):39–43. (In Russ).].Bond T. Third clinical trial reinforces the use of the GeneSight® pharmacogenomic test. Pharmacogenomics. 2014;15(3):257. DOI: 10.2217/pgs.14.7Bond T. Third clinical trial reinforces the use of the GeneSight® pharmacogenomic test. Pharmacogenomics. 2014;15(3):257. DOI: 10.2217/pgs.14.7Genesight.com [Internet]. GeneSight test [cited 2022 Oct 19]. Available from: https://genesight.com/.Genesight.com [Internet]. GeneSight test [cited 2022 Oct 19]. Available from: https://genesight.com/.Howland RH. Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv. 2014;52(11):13–16. DOI: 10.3928/02793695-20141021-09Howland RH. Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv. 2014;52(11):13–16. DOI: 10.3928/02793695-20141021-09Dynacare [Internet]. Genecept Assay [cited 2022 Oct 19]. Available from: https://www.dynacare.ca/patients-and-individuals/health-solutions/mental-health-solutions.aspx.Dynacare [Internet]. Genecept Assay [cited 2022 Oct 19]. Available from: https://www.dynacare.ca/patients-and-individuals/health-solutions/mental-health-solutions.aspx.Lara DV, Melo DO, Silva RAM, Santos PCJL. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021;22(8):505–513. DOI: 10.2217/pgs-2020-0187Lara DV, Melo DO, Silva RAM, Santos PCJL. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021;22(8):505–513. DOI: 10.2217/pgs-2020-0187Kumar A, Kearney A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021;33(11):849–851. Published 2021 Nov 10. DOI: 10.1097/JXX.0000000000000666Kumar A, Kearney A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021;33(11):849–851. Published 2021 Nov 10. DOI: 10.1097/JXX.0000000000000666Gardner KR, Brennan FX, Scott R, Lombard J. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J. 2014;2014:730956. doi: 10.1155/2014/730956Gardner KR, Brennan FX, Scott R, Lombard J. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J. 2014;2014:730956. doi: 10.1155/2014/730956Genecards.org [Internet]. CYP1A1 Gene — Cytochrome P450 Family 1 Subfamily A Member 1 [cited 2022 Oct 19]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP1A1.Genecards.org [Internet]. CYP1A1 Gene — Cytochrome P450 Family 1 Subfamily A Member 1 [cited 2022 Oct 19]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP1A1.Genecards.org [Internet]. CYP1B1 Gene — Cytochrome P450 Family 1 Subfamily B Member 1 [cited 2022 Oct 19]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP1B1.Genecards.org [Internet]. CYP1B1 Gene — Cytochrome P450 Family 1 Subfamily B Member 1 [cited 2022 Oct 19]. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP1B1.Proteinatlas.org [Internet]. The Human Protein Atlas: CYP1A1 [cited 2022 Oct 19]. Available from: https://www.proteinatlas.org/ENSG00000140465-CYP1A1/tissue.Proteinatlas.org [Internet]. The Human Protein Atlas: CYP1A1 [cited 2022 Oct 19]. Available from: https://www.proteinatlas.org/ENSG00000140465-CYP1A1/tissue.

The authors declare that there are no conflicts of interest present.